



Genetic Diversity of HIV-1 and Transfusion Safety : Systematic Review and Concepts Analysis

Christian Mangala^{1,2*}, Joseph Fokam^{1,3,4}, Denis Maulot Bangola^{1,2}
and Thérèse Nkoa^{1,4}

¹Catholic University of Central Africa (CUCA), Cameroon.

²National Public Health Laboratory (NPHL), Gabon.

³Chantal Biya International Reference Center (CBIRC), Cameroon.

⁴University of Yaoundé 1 (UY-1), Cameroon.

Authors' contributions

This work was carried out in collaboration among all authors. Author CM designed the study and designed it with authors TN and JF. Author CM wrote the article. All authors have reviewed, read, and accepted the final manuscript.

Article Information

DOI: 10.9734/ISRR/2021/v10i330132

Editor(s):

(1) Dr. Seema Sharma, University of health sciences Rohtak, India.

Reviewers:

(1) Mburu Samuel, Kirinyaga University, Kenya.

(2) I S Chaitanya Kumar, India.

Complete Peer review History: <https://www.sdiarticle4.com/review-history/70484>

Review Article

Received 02 April 2021

Accepted 08 July 2021

Published 04 August 2021

ABSTRACT

Background: The genetic diversity of human immunodeficiency virus type 1 (HIV-1) is a real problem facing blood banks. This genetic diversity has a negative impact on diagnostic strategies within the transfusion chain by weakening the security of the donation. The objective of this study is to clarify the concepts emanating from the research project entitled : «Genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion in Gabon».

Methods: This study was the result of a systematic review and a conceptual analysis of several studies that were systematically searched for in databases (PubMed, Google Scholar, and Medline), and whose object was focused on the genetic diversity of HIV -1 and its impact on transfusion safety. Indeed, the information relating to the concepts coming from the full articles was used. These were obtained by reading the most relevant articles. All relevant studies reporting data on HIV-1 genetic diversity and blood safety published in English between January 2012 and December 2020 have been identified for context. The method of conceptual analysis of « Walker and Avant (2005) » was used to clarify the different concepts of our study. The correlation test was used to show the relationship between the concepts.

Results: This systematic review and conceptual analysis study made it possible to determine the variables and to clarify the different concepts (HIV-1, Genetic diversity, Blood transfusion, Residual risk) essential for carrying out our research project entitled: "Genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion". This model made it possible to show the effect of the genetic diversity of HIV-1 on the residual risk in blood transfusion using as model variables : viral load and serological markers (Antibodies and P24 Antigen). Knowledge of molecular strains (URF, CRF, subtypes) during this study made it possible to better identify the molecular strains most involved in the residual risk. Despite its complexity, this conceptual analysis contributed enormously to the understanding of the activities and the quantifiable and non-quantifiable components that participated in our study. Statistical analysis showed that the HIV-1 concept was significantly related to the other three concepts with $P = 0.001$. Likewise for the concept of genetic diversity was also significantly linked to the two other concepts with $P = 0.003$.

Conclusion: The genetic diversity of HIV-1 in the blood transfusion environment contributes significantly to the transmission of HIV from donor to recipient. The mastery of these molecular strains is essential for the various blood banks to ensure a safe blood supply.

Keywords: HIV-1; blood transfusion; genetic diversity; residual risk.

1. INTRODUCTION

The human immunodeficiency virus (HIV) is still present in the world's population. Nevertheless, the most recent data from the World Health Organization (WHO) still show that there are annually nearly 2 million new people infected with HIV and with 36.9 million people living with this chronic infection. in 2020 [1,2].

The molecular epidemiology of HIV around the world reveals that all strains are found in Sub-Saharan Africa in general and Central Africa in particular with an overwhelming majority of non-B strains. These molecular strains could negatively impact the safety of blood donation in these endemic countries [1,3,4]. The geographic distribution of HIV strains differs from continent to continent, region to region. But population movements including immigration, tourism, and international travel are changing the molecular map of HIV every day, which is no longer static. This constitutes a health problem, especially in an African transfusion environment [5].

Blood transfusion goes a long way in improving the health of patients. It intervenes especially in anemic children due to malaria, in sickle cell disease, in pregnant women, and surgical interventions. But this intervention must be carried out within the safety standards of the blood donation throughout the transfusion chain [6].

Transfusion safety in blood banks is a major concern that concerns all stakeholders in blood donation around the world in general and in particular in countries with limited resources.

Blood transfusion safety is still far from being mastered in African countries [7]. In general, in blood banks, there are more voluntary and family donors who mobilize for the donation. As a result, the risk of transmission of pathogens is higher in this category of donors [8,9]. The threat to the safety of donating blood can be linked on the one hand to the existence of different molecular strains in donors which lead to the variability of the antigens, which gives rise to the possibility of antibodies of low affinity towards "standard HIV subtype B" antigens used by screening tests [10,11].

And these molecular variants make screening difficult and undermine transfusion safety. This further shows the need to improve all transfusion safety conditions, at the start and the end of the transfusion chain to ensure a blood supply devoid of any pathogens.

This study based on a systematic review and an analysis of concepts, aims to clarify the different concepts of the research project entitled « genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion in Gabon ».

2. METHODS

2.1 Study Design

This study is part of a research project on "the genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion in Gabon". This study was the result of a systematic review and concept analysis of several studies that focused on the genetic diversity of HIV-1 and blood safety. Indeed, we used information relating to

the concepts from the full articles. These were obtained by reading the most relevant articles. All relevant studies reporting data on HIV-1 genetic diversity and blood safety published in English between January 2012 and December 2020 have been identified for context. It will be a question here of analyzing the different concepts of our study using the method of conceptual analysis of « Walker and Avant (2005) » which will allow us to clarify the different concepts. And for that, we must begin to define the concept, give the goal of the analysis, present the different uses of the concept, enumerate the attributes of the concept, the empirical referents, the antecedents, and consequences of the concept.

2.2 Research Question

The research question for our concept analysis study is : « Do HIV and blood transfusion researchers share the same concepts to describe the genetic diversity of HIV-1 ? ». This research question clarified all the different articulations of concepts related to the context of the study.

2.3 Research Strategy

Studies on the genetic diversity of HIV-1 and transfusion safety were systematically searched for in the various databases, namely PubMed, MEDLINE, Google Scholar and we carried out a manual search in the main transfusion journals. This data search was performed using the following search terms, alone or in combination : « HIV-1 », « genetic diversity », « blood transfusion », « residual risk », « blood safety » and « transfusion transmissible infections ».

2.4 Selection Criteria

The preferred reporting elements for systematic reviews and meta-analysis (PRISMA) of the 2020 guidelines served as a template for the report of this review [12]. Full articles were independently reviewed by two people from the research team for inclusion in the study. But in the event of disagreement between the two researchers, a third researcher is consulted in order to settle this situation. Out of 2106 studies (full articles) that were generated in the different databases, 1008 full articles were deleted with the reason for the presence of duplicates. The independent selection carried out by two reviewers made it possible to retain 172 full articles for a more rigorous evaluation. Then after the evaluation, 90 (52.3%) were retained for the conceptual

analysis, and 82 (47.7%) full articles were excluded because they did not contain conceptual definitions of the different concepts. The studies selected met the eligibility criteria, namely published studies looking at the genetic diversity of HIV-1 and transfusion safety, and defining the different study concepts. On the other hand for non-inclusion criteria, these articles were excluded for various reasons such as studies lasting more than 10 years, not defining the concepts, non-coherent and non-exploitable information, and other reasons not allowing to combine these studies with our study (Fig. 1).

2.5 Quality of the Studies Included

The methodological quality of the included studies was assessed using the 9-point scoring system developed by Stanifer et al. [13]. The studies were assessed according to the scoring criteria. If the score was between 1-3, 4-6 or 7-9 then the quality of the studies was rated respectively as low, medium, or high. The authors counted the number of appearances of the different study concepts in each selected article. This made it possible to determine the importance of each concept. This methodology also made it possible to identify the differences and existing relationships between the concepts or between the study variables.

2.6 Data Abstraction

Data extraction was done independently to acquire relevant information contributing to the conduct of this study. And if there was a difference of opinion between the two people responsible for the extraction, a third person was invited to resolve the ambiguity to reach a consensus. All data from eligible studies were extracted. All data abstractions have been verified by all members of the research team. However, studies for which data were not obtained were simply excluded from our study.

2.7 Content Analysis

All full papers that included a conceptual definition of the approach centered on HIV-1 genetic diversity and blood safety were included in the study and submitted for subsequent conventional content analysis, to develop codes based on the actual data, ie in the definitions identified [14]. Each definition was identified and divided into meaningful units which we subsequently coded. The coding sheet was




Fig. 1. Flow Diagram for the selection of studies

developed through an iterative process. One author randomly selected 50 full-length articles and initially coded the included definitions to develop a preliminary coding sheet. This process continued until the full articles were exhausted. Coding of full articles was done independently by two members of the research team. The discrepancies that emerged from these multiple coding strategies provided valuable information to refine the coding scheme and were resolved by a discussion [15]. The codes were grouped into significant groups, that is to say, were aggregated into different dimensions centered on the genetic diversity of HIV-1 and blood safety. The coding method had also made it possible to determine the number of times the concept had appeared in each full article. For the concept of

HIV-1, it appeared 7,206 times in all eligible articles included in the study. 4,146 times for the concept of genetic diversity, 4,516 times for the concept of blood transfusion and 5,042 times for the concept of residual risk.

2.8 Statistical Analysis

To show the existing relationship between the different concepts, using the coding method allowed us to use the correlation test to determine the Pearson coefficient to show the existing relationship between the different concepts. All data obtained by the coding method was used in digital form. The normality test was used for all variables. Statistical analysis showed that the HIV-1 concept was significantly related

to the other three concepts (Genetic diversity, Residual risk, and blood transfusion) with $P = 0.001$. Likewise for the concept of genetic diversity was also significantly linked to the two other concepts (Residual risk and transfusion) with $P = 0.003$.

3. RESULTS

The choice of these concepts takes into account the field of interest so that the results resulting from the conceptual analysis contribute significantly to the advancement of knowledge and better clarify our research project which is entitled : « Genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion in Gabon ». The conceptual terms for this study are Human Immunodeficiency Virus type 1, Blood transfusion, HIV-1 genetic diversity, and residual risk (Table 1).

3.1 Human Immunodeficiency Virus type 1 (HIV-1)

Several authors defining the concept of HIV agree that HIV is a virus belonging to the Retroviridae family and the genus Lentivirus, which attacks cells of the immune system and destroys them or renders them ineffective. The concept's history stems from animal interspecies contact, although essential to life on earth and evolution, sometimes leads to the transmission of infectious agents to a new host ill-adapted to combat this new pathogen. Indeed, before becoming HIV, this virus had as its first host the chimpanzee, the respective denomination of which is the Simian Immunodeficiency Virus (SIV). It was during a hunt that the man confronted the chimpanzee infected with SIV. During this confrontation, the chimpanzee will inflict a wound on the hunter which will be the route of transmission of the virus from the chimpanzee to humans. This virus-changing host would later be called Human Immunodeficiency Virus (HIV). The goal of the analysis of the HIV-1 concept is to clarify it in all these possible articulations that can lead to understanding the concept clearly and simply. This concept is widely used in clinical practice but also other fields. Yet the contextual basis of this concept is rarely if ever, questioned in medical disciplines. By this, we mean that the situational, relational, temporal, socio-cultural, and clinical contexts in which the concept is relevant, used effectively, and applied in various situations have not been critically examined by these disciplines. The different uses used by some authors are

seropositive, AIDS, and serological status. But it is important not to confuse the concept of HIV and AIDS because HIV is a virus of the lentivirus genus while AIDS is a clinical syndrome where there is an immune deficiency in humans. For example, people living with HIV, HIV prevalence, HIV prevention, HIV testing, AIDS diagnosis, AIDS response, national AIDS program, organizations supporting people with AIDS, etc. All these terms refer populationally to HIV-1, which is the virus in question. Several authors use the concept HIV-1 to designate the disease of AIDS to better explain and be better understood by the different layers of the population, but on the other hand, others say that the use of the concept HIV-1 instead of AIDS n is not appropriate as it causes confusion among users. For them, AIDS does not mean HIV-1 and its cause is not caused only by HIV-1 because other germs can induce this syndrome in humans. Likewise, for the use of serological, seropositive, and antiretroviral status, these are uses that directly refer to the concept of HIV-1 in the medical field. Concept attributes are the main characteristics that allow us to designate or describe the concept. The information gathered from all of the selected articles was then analyzed to identify their attributes. Attributes are commonly used to describe the concept through the literature review. The attributes identified in this analysis identify situations, phenomena, experiences, and practices that fall within the concept of HIV-1 or which can be appropriately characterized using the concept of HIV-1. Conceptual analysis shows that transmission of HIV can also occur through the blood.

3.2 Blood Transfusion

Blood transfusion is a therapeutic intervention that makes it possible to reabsorb a deficiency in labile blood products (LBP) in many patients by saving their lives in certain circumstances (accidents, anemia, surgical interventions, etc.). The use of this concept is encountered in the field of transfusion medicine and allows a supply of labile blood products from a donor to a recipient. The information gathered from the literature review was then analyzed to identify the attributes of this concept. However, these attributes are commonly used to describe and designate the concept. The attributes identified in this conceptual analysis make it possible to identify situations, phenomena, and modifications directly affecting the concept as a whole. As attributes of the concept of blood transfusion, the most used are blood donation, donor, blood

bank, transfusion risk, and transfusional setting. In this specific model case, it is important to show that blood transfusion is framed by two barriers, namely medical interview and biological qualification, which ensure transfusion safety. But also to show that these different attributes make it possible to designate and describe the concept of blood transfusion in all these components. Related cases also show that a blood donor can transmit a pathogen to a recipient during the transfusion if the safety of the donation is not well ensured.

3.3 Genetic Diversity

Genetic diversity refers to the plurality, to the molecular variability of the human immunodeficiency virus type 1. But other authors define it as the major characteristic of HIV. This diversity is made up of several molecular strains which recombine over time. Genetic diversity is then the set of characteristics of a viral species in its molecular dimension. The use of genetic diversity is much more encountered in molecular biology. Some authors use words like genetic variability, variants to express the concept. The information gathered from all the articles selected was then analyzed to identify the attributes of this concept. However, these attributes are commonly used to describe and denote the

concept of genetic diversity. The attributes identified in this conceptual analysis make it possible to find situations, phenomena, molecular modifications directly affecting the concept of genetic diversity as a whole. As attributes of the concept of genetic diversity, these are molecular variability, molecular variants, and molecular strains. Mutations, subtypes, and recombinant forms (CRF and URF) are also attributes of the concept of genetic diversity. The analysis of the concept of genetic diversity will make it possible to choose the best quantifiable variables that can explain the concept in all its articulations to better understand it. And these same variables of the concept will help to show the implication of genetic diversity on the residual risk in the transfusion environment. Note that knowledge of the variables of the concept has assets in the mastery of epidemiological data and virological monitoring in a patient.

3.4 Residual Risk

Some authors define residual risk as to the risk of transmission of a pathogen during a transfusion, despite the measures of donor selection and screening for biomarkers of viral infection. On the other hand, our definition is this : the residual risk is the risk of transmission of an

Table 1. Summary of the conceptual analysis

Analysis tools	Concepts			
	HIV-1	Genetic diversity	Blood transfusion	Residual risk
Attributes	HIV positive Serological statut AIDS	Molecular variability Molecular variants	Blood donation Donor	No specific attribute
Empirical referents	Anti-HIV-1 Ab AgP24 RNA (viral load)	Mutation CRF URF	Biological qualification	Negative serology Positive viral load
Consequences	Chronic infection (HIV-1)	Impact on diagnosis Therapeutic impact	Exposure of the recipient to infections	Acquisition of a chronic disease (case of HIV)
Number of concept appearances	7,206 times	4,146 times	4,516 times	5,042 times
Relationship	Blood Transfusion Genetic Diversity Residual Risk:	Blood Transfusion Residual Risk	Residual Risk HIV-1	Blood Transfusion HIV-1
Benefit of this analysis	Clarification of measurable variables and readjustment of the theme			

AIDS : Acquired ImmunoDeficiency Syndrome; AgP24 : P24 antigen; RNA : RiboNucleic Acid; CRF : Circulating Recombinant Form; URF :Unique Recombinant Form; HIV-1 : Human immunodeficiency virus type 1 ; Anti-HIV-1 Ab : Anti-HIV-1 antibodies

infectious agent from a seronegative donor and of a positive viral load to a recipient during the transfusion despite the taking into account of safety measures. In our current context, this concept is widely used in the field of transfusion. Some authors use it in transfusions of blood and human organs in transfusion medicine. The information collected from all the studies selected was then analyzed to identify no possible attribute that could describe the concept of residual risk in its entirety. The residual risk is still high in some countries around the world given the screening strategies in place that do not respond to the evolution and molecular modification of pathogens, such as HIV-1. The blood supply devoid of any infectious entity is beneficial to the recipient. The emergence of new infections transmissible by transfusion threatens the quality of blood donation, which makes sense to rigorously support screening strategies in blood banks, especially for countries with limited resources.

3.5 Relational Model

The conceptual analysis made it possible to determine the variables essential for carrying out this research project entitled : "Genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion in Gabon". Speaking of variables, we can cite viral load, serological markers (anti-HIV antibodies and P24 antigen). This model has shown the effect of genetic diversity on the residual risk in blood transfusion. Knowledge of molecular strains (URF, CRF, subtypes) during this study made it possible to better identify the molecular strains most involved in the residual risk. Despite its complexity, this conceptual analysis has contributed enormously to the understanding of the activities and the quantifiable and non-quantifiable components that participate in this study.

4. DISCUSSION

The transmission of transfusion-transmissible infections is still a concern for those in charge of blood banks in different world countries. The genetic diversity of HIV-1 is an illustration of the threat to blood safety, especially in endemic countries (with high prevalence). Our systematic review and conceptual analysis study looked at the effect of genetic diversity in HIV-1 on residual risk in transfusion settings. Conceptual analysis revealed that the genetic diversity of HIV-1 had an impact on the residual risk in the transfusional

environment. For this, it would be necessary to quantify all the variables of concept, namely : the viral load and the serological markers (anti-HIV antibodies and P24 antigen) and to determine the molecular strains in question. HIV-1 viral load has been shown by some authors to play an important role in interpreting health status, infectivity, and response to treatment [16,17,18,19]. The use of viral load allows speculation about the concept of HIV-1. Therefore, the conceptual analysis of this study made it possible to choose the viral load as the quantifiable variable par excellence of this study given its presence in several conceptual joints of viral transmission. It has also shown the involvement of the molecular components of HIV-1 on the residual risk in blood transfusion [20,21,22]. The serological markers (anti-HIV Ab, AgP24) identified as secondary variables to the concept by their presence throughout the infection would also contribute to the diagnosis of HIV-1 and the interpretation of recent or chronic infection [23]. The empirical referents were viral load and serological markers. Several authors have shown that in seropositive donors receiving antiretroviral treatment and having an undetectable viral load could have an impact on the residual risk in the transfusion environment [24,25,26]. Therefore, in such a situation, virus screening should necessarily involve detection of the viral load by molecular techniques such as RT-PCR and NAT. Transfusion safety is an approach aimed at ensuring the quality of the blood donation and protecting the recipient from any infectious intrusion [27,28,29,30,31]. Nowadays, the demand for blood donation is increasing every day in hospitals around the world, which goes without saying to improve the blood safety system, also taking into account the emergence of infectious diseases transmissible by transfusion [32,33,34,35]. Blood transfusion is one of the routes of transmission of pathogens. Therefore, the security of the donation should be ensured throughout the transfusion chain. Regarding this study, a blood transfusion would be limited to the level of risk of viral transmission of HIV-1. Viral infections threaten the safety of donation in the transfusion environment. Several factors, especially for viral infections, are thought to increase the risk of viral transmission in a transfusion environment [36,37,38,39,40]. Mutations and molecular variants could have a negative impact on the safety of the donation if the screening techniques used do not have a high sensitivity to detect the molecular strain involved. As a result, the recipient would be exposed to any viral transmission and this could

alter the vital prognosis of this recipient. Several authors have shown that the consequence of passive blood safety is exposure to infectious agents transmissible by transfusion. To estimate the efficiency of the transfusion chain, it is necessary a priori determine the transfusion risk [41-45]. Today much has been done with the aim of improving the diagnostic tests used in blood banks, but this does not exclude that these tests have limits (existence of the detection threshold) that could be caused by the genetic diversity of HIV-1 whose mutations are seen every day in infected patients. A recent study carried out in Cameroon reveals that there is a risk of the appearance of a new recombinant form of HIV-1 MO, the detection of which would require appropriate diagnostic tools [46-48]. This study would further show that the genetic diversity of HIV-1 would have an impact on the diagnosis and therefore on the residual risk in blood transfusion. Analysis of this concept would further situate the impact of molecular strains of HIV-1 on residual risk. Some studies have shown that viral load and serology (Antibodies and P2 antigens) were essential in interpreting data evaluating the effectiveness of the donation security system put in place to reduce the risk of HIV transmission in transfusion [1,49-52]. The number of times each concept appears shows its importance in the various full articles included in the study. This would explain that these concepts have been fully exploited by the various authors given their degree of importance. And the correlation test showed that the concepts in this study were significantly related ($P = 0.001$) to each other. This further confirms the importance of this study at the transfusion level.

5. CONCLUSION

The conceptual analysis of this study made it possible to better understand the research project entitled "Genetic diversity of HIV-1 and its effect on the residual risk in blood transfusion in Gabon" and to fill the existing gaps. It also allowed the readjustment of certain component of the study. The genetic diversity of HIV-1 has a considerable influence on the risk of transmission of HIV-1 in the transfusion environment. Ultimately, it should be noted that the conceptual analysis reinforced the scope of this research project in all these scientific and social connections. And also the theme does not present any ambiguity that could have a negative impact on the research activities of this project.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

The authors wish to thank all the reviewers and all the staff of the Doctoral Training Unit of the School of Health Sciences of the Catholic University of Central Africa in Yaounde (Cameroon) for the services offered during the period of writing this article.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Olusola BA, Olaleye DO, Odaibo GN. Detection of Early HIV-1 infection among febrile persons and blood donors in Oyo State, Nigeria. Cold Spring Harbor Laboratory; 2020 Apr 14; DOI :10.1101/2020.04.09.20058966
2. World Health Organization. VIH/ SIDA : Recommendations. I recovered the web on June 10 ; 2021.
3. Rupp S, Ambata P, Narat V, Giles-Vernick T. Beyond the cut hunter: A historical epidemiology of HIV beginnings in Central Africa. EcoHealth [Internet]. Springer Science and Business Media LLC. 2016; 13(4):661–71. DOI :10.1007/s10393-016-1189-6
4. Bes M, Piron M, Casamitjana N, Gregori J, Esteban JI, Ribera E, et al. Epidemiological trends of HIV-1 infection in blood donors from Catalonia, Spain (2005-2014). Transfusion [Internet]. Wiley. 2017 Jul 5;57(9):2164–73. DOI :10.1111/trf.14195
5. Seck M, Dièye B, Guèye YB, Faye BF, Senghor AB, Toure SA, et al. Évaluation de l'efficacité de la sélection médicale des donneurs de sang dans la prévention des agents infectieux. Transfusion Clinique et Biologique [Internet]. Elsevier BV. 2016;23(2):98–102. DOI :10.1016/j.tracli.2015.11.001

6. Jacquot C, Delaney M. Efforts toward elimination of infectious agents in blood products. *Journal of Intensive Care Medicine* [Internet]. SAGE Publications; 2018 ;33(10):543–50.
DOI :10.1177/0885066618756589
7. Morar MM, Pitman JP, McFarland W, Bloch EM. The contribution of unsafe blood transfusion to human immunodeficiency virus incidence in sub-Saharan Africa: reexamination of the 5% to 10% convention. *Transfusion* [Internet]. Wiley. 2016;56(12):3121–32.
DOI :10.1111/trf.13816
8. Police SMC, Bessanguem B, Mofini E, Elowa B, Service G, Guéréndo P, et al. High prevalence of hepatitis B virus infection compared to human immunodeficiency virus among blood donors in Bangui. *Open Journal of Gastroenterology* [Internet]. Scientific Research Publishing, Inc. 2020;10(06):137–43.
DOI:10.4236/ojgas.2020.106014
9. Ajugwo AO, Erhabor TA, Eledo BO, Eze RI, Digban KA. Prevalence of transfusion transmissible infections in a Nigerian Tertiary Hospital. *Journal of Transmitted Diseases and Immunity* [Internet]. Scitechnol Biosoft Pvt. Ltd. 2017;01(02).
DOI :10.21767/2573-0320.100011
10. Pessôa R, Loureiro P, Esther Lopes M, Carneiro-Proietti ABF, Sabino EC, Busch MP, et al. Ultra-deep sequencing of HIV-1 near full-length and partial proviral genomes reveals high genetic diversity among brazilian blood donors. Kaderali L, editor. *PLOS ONE* [Internet]. Public Library of Science (PLoS). 2016 Mar 31;11(3):e0152499.
DOI :10.1371/journal.pone.0152499
11. Zhao J, Lv X, Chang L, Ji H, Harris BJ, Zhang L, et al. HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China. *Scientific Reports* [Internet]. Springer Science and Business Media LLC. 2020;10(1).
DOI:10.1038/s41598-020-64463-w
12. Page MJ, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow CD, et al. Updating guidance for reporting systematic reviews : Development of the PRISMA 2020 statement. *Center for Open Science*; 2020.
DOI :org/10.31222/osf.io/jb4dx.
13. Tetzlaff J, Page M, Moher D. PNS154 the prisma 2020 statement : development of and key changes in an updated guideline for reporting systematic reviews and meta-analyses. *value in health* [internet]. Elsevier bv. 2020;23:S312-S313.
DOI :org/10.1016/j.jval.2020.04.1154
14. Renz SM, Carrington JM, Badger TA. Two strategies for qualitative content analysis: an intramethod approach to triangulation. *Qualitative Health Research* [Internet]. SAGE Publications. 2018;28:824-31.
DOI:10.1177/1049732317753586
15. Williams V, Boylan AM, Nunan D. Critical appraisal of qualitative research: necessity, partialities and the issue of bias. *BMJ Evidence-Based Medicine* [Internet]. BMJ. 2020;25:9-11. DOI :10.1136/bmjebm-2018-111132
16. Crispim MAE, Reis MNG, Abraham C, Kiesslich D, Fraiji N, Bello G, et al. Homogenous HIV-1 subtype B from the Brazilian Amazon with infrequent diverse BF1 recombinants, subtypes F1 and C among blood donors. Chemin I, editor. *PLOS ONE* [Internet]. Public Library of Science (PLoS). 2019 ;14:e0221151.
DOI:10.1371/journal.pone.0221151
17. Lecher SL, Fonjungo P, Ellenberger D, Toure CA, Alemnji G, Bowen N, et al. HIV viral load monitoring among patients receiving antiretroviral therapy — eight Sub-Saharan Africa Countries, 2013–2018. *MMWR Morbidity and Mortality Weekly Report* [Internet]. Centers for Disease Control MMWR Office. 2021;70(21): 775–8.
DOI:10.15585/mmwr.mm7021a2
18. Zeng P, Liu Y, He M, Wang J, Keating S, Mao W, et al. The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012–2014. Lin W, editor. *PLOS ONE* [Internet]. Public Library of Science (PLoS). 2017 Jun 16;12(6):e0179328.
DOI:10.1371/journal.pone.0179328
19. Hu, Y. *Molecular Techniques for Blood and Blood Product Screening*. *Advanced Techniques in Diagnostic Microbiology* 2018 ; 10 : 31–66.
20. Chow WZ, Bon AH, Keating S, Anderios F, Halim HA, Takebe Y, et al. Extensive genetic diversity of HIV-1 in incident and prevalent infections among Malaysian Blood Donors: Multiple Introductions of HIV-1 Genotypes from Highly Prevalent Countries. Paraskevis D, editor. *PLOS*

- ONE [Internet]. Public Library of Science (PLoS). 2016;11(8):e0161853. DOI:10.1371/journal.pone.0161853
21. Liang S, Liu Z, Wang S, Liu J, Shi L, Mao W, et al. The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014–2017. Zhang C, editor. PLOS ONE [Internet]. Public Library of Science (PLoS). 2020 Dec 21;15(12):e0243650. DOI:10.1371/journal.pone.0243650
 22. Aprahamian H, Bish DR, Bish EK. Residual risk and waste in donated blood with pooled nucleic acid testing. *Statistics in Medicine*, 2016 ; 35 : 5283–5301. Doi:10.1002/sim.7066 .
 23. Van Tienen C, Rugebregt S, Scherbeijn S, Götz H, Geurts van Kessel C. The performance of the Alere HIV combo point-of-care test on stored serum samples; useful for detection of early HIV-1 infections? *Sexually Transmitted Infections* [Internet]. *BMJ*. 2017;94(5):331–3. DOI :10.1136/sextrans-2016-052818
 24. Obeng BM, Bonney EY, Asamoah-Akuoko L, Nii-Trebi NI, Mawuli G, Abana CZY, et al. Transmitted drug resistance mutations and subtype diversity amongst HIV-1 seropositive voluntary blood donors in Accra, Ghana. *Virology Journal* [Internet]. Springer Science and Business Media LLC. 2020 ;17(1). DOI:10.1186/s12985-020-01386-y
 25. Vubil A, Jani VI , Mabunda N, Ismael N, Ramalho D, Morgado MG, et al. Genetic diversity and transmitted drug resistance of HIV-1 subtypes in blood donors candidates in northern mozambique. *Journal of AIDS & Clinical Research* [Internet]. OMICS Publishing Group. 2016;7(10). DOI:10.4172/2155-6113.1000623
 26. Matsumoto C, Shinohara N, Sobata R, Uchida S, Satake M, Tadokoro K. Genetic Analysis of HIV-1 in Japan: a Comprehensive Analysis of Donated Blood. *Japanese Journal of Infectious Diseases* [Internet]. Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis; 2017;70(2):136–42. DOI : 10.7883/yoken.jjid.2015.504
 27. Kiely P, Gambhir M, Cheng AC, McQuilten ZK, Seed CR, Wood EM. Emerging infectious diseases and blood safety: modeling the transfusion-transmission risk. *Transfusion Medicine Reviews* [Internet]. Elsevier BV. 2017;31(3):154–64. DOI :10.1016/j.tmr.2017.05.002
 28. Kramer K, Zaaier HL, Verweij MF. The Precautionary Principle and the Tolerability of Blood Transfusion Risks. *The American Journal of Bioethics* [Internet]. Informa UK Limited; 2017;17(3):32–43. DOI :10.1080/15265161.2016.1276643
 29. Mathur A, Dontula S, Jagannathan L. A study of centralized individual donor nucleic acid testing for transfusion transmitted infections to improve blood safety in Karnataka, India. *Glob J Transfus Med* 2017 ; 2 : 24-32. DOI: 10.4103/gjtm.gjtm_8_17
 30. Rocha D, Andrade E, Godoy DT, Fontana-Maurell M, Costa E, Ribeiro M, et al. The Brazilian experience of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in blood donors. *Transfusion* [Internet]. Wiley; 2018 ;58(4):862-70. Doi.org/10.1111/trf.14478.
 31. Hans R, Marwaha N, Sharma S, Sachdev S, & Sharma RR. Initial trends of individual donation nucleic acid testing in voluntary & replacement donors from a tertiary care centre in north India. *Indian J Med Res* 2019, 149 : 633-640.
 32. O'Brien SF, Yi QL, Fan W, Scalia V, Goldman M, Fearon MA. Residual risk of HIV, HCV and HBV in Canada. *Transfusion and Apheresis Science* [Internet]. Elsevier BV. 2017;56(3):389-91. DOI :10.1016/j.transci.2017.03.010
 33. Dodd RY. Emerging infections and transfusion safety. *Practical Transfusion Medicine* [Internet]. Wiley. 2017 Mar 10;176-83. DOI:10.1002/9781119129431.ch17
 34. Awan SA, Junaid A, Sheikh S. Transfusion transmissible infections: Maximizing donor surveillance. *Cureus* [Internet]. Cureus, Inc.; 2018 Dec 28. DOI:10.7759/cureus.3787
 35. Dadzie I, Muniru S, Adu P, Cudjoe O. Nucleic Acid Amplification Testing Detects HIV Transmission Risk in Serologically-Tested Blood Donor Units. *Journal of Clinical and Diagnostic Research*. 2018;12 :DC22-DC24 . DOI :10.7860/jcdr/2018/36141.12056
 36. Waheed U, Noor FA, Saba N, Wazeer A, Qasim Z, Arshad M, et al. Genetic diversity of human immunodeficiency virus type 1 in

- asymptomatic blood donors in Islamabad, Pakistan. *Journal of Laboratory Physicians* [Internet]. Georg Thieme Verlag KG. 2020 Aug;12(02):092–7. DOI:10.1055/s-0040-1716593
37. Vieira PCM, Lamarao LM, Amaral CEM, Correa ASM, Lima MSM, Barile KAS, et al. Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil. *Transfusion*. 2017 ;57 :1968–1976.
DOI: 10.1111/trf.14146
 38. Yooda AP, Sawadogo S, Soubeiga ST, Obiri-Yeboah D, Nebie K, Ouattara AK, ... Simpore J. Residual risk of HIV, HCV, and HBV transmission by blood transfusion between 2015 and 2017 at the Regional Blood Transfusion Center of Ouagadougou, Burkina Faso. *Journal of Blood Medicine* 2019 ; 10 : 53–58.
 39. Dongmo EG, Nsagha DS, Zofou D, Longdoh Njunda A. , Nanfack AJ, Fokam, J & Tayou Tagny, C. Residual risk of HIV transmission through blood transfusion in five blood banks in Cameroon. *The Journal of Medical Research* 2020 ; 6: 158-165.
 40. Souza JC, Crispim MAE, Abraham C, Fraiji NA, Kiesslich D, Stefani MMA. High rate of seromarkers for HIV, HBV and syphilis among blood donors using confidential unit exclusion, before and after HIV-NAT implementation at a major public blood bank in the Brazilian Amazon. *Transfusion* [Internet]. Wiley; 2018 ;59(2):629–38. DOI:10.1111/trf.15045.
 41. Ghosh K, Misra K. HIV risk associated with nucleic acid testing tested seronegative blood donation where the donor was not preassessed for the risk. *Asian Journal of Transfusion Science* [Internet]. Medknow. 2017;11(2):213.
DOI:10.4103/ajts.ajts_136_16
 42. Aramani SS, Bommanahalli BP, Kammar SM. Efficacy of Nucleic Acid Amplification Test (NAT) over Enzyme Linked Immuno Sorbent Assay (ELISA) in Detecting Transfusion Transmissible Infections (TTI) among blood donors at a tertiary care centre. *Annals of Pathology and Laboratory Medicine* [Internet]. Marwah Infotech. 2019 Apr 29;6(4):A244–247. DOI :10.21276/apalm.2453
 43. Mangala C, Fokam J, Maulot-Bangola D, Moundanga M, Nkoa T. Residual risk of HIV in African transfusional setting: Systematic review and meta-analysis. *International STD Research & Reviews* [Internet]. Sciencedomain International. 2021;25–36.
DOI : 10.9734/isrr/2021/v10i230129
 44. Tee KK, Bon AH, Chow WZ, Ng KT, Chan KG, Kamarulzaman A, et al. Genome Sequence of a Novel HIV-1 Circulating Recombinant Form (CRF77_cpx) Identified among Blood Donors in Malaysia. *Genome Announcements* [Internet]. American Society for Microbiology; 2017 Jun 29;5(26).
DOI:10.1128/GENOMEA.00459-17
 45. He W, Han X, An M, Hai Y, Chang L, Liu C, et al. Near Full-Length Genome Sequence of a Novel HIV-1 Second-Generation Recombinant Form (CRF01_AE/CRF07_BC) Detected Among Blood Donors in North China. *AIDS Research and Human Retroviruses* [Internet]. Mary Ann Liebert Inc; 2017 Dec;33(12):1265–9.
Doi:10.1089/aid.2017.0111
 46. De Oliveira F, Mourez T, Vessiere A, Ngoupo PA, Alessandri-Gradt E, Simon F, et al. Multiple HIV-1/M + HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon. *Retrovirology* [Internet]. Springer Science and Business Media LLC. 2017;14(1).
DOI :10.1186/s12977-016-0324-3
 47. Weimer A, Tagny CT, Tapko JB, Gouws C, Tobian AAR, Ness PM, et al. Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century. *Transfusion* 2019 ; 59 : 412-427.
 48. Ware AD, Jacquot C, Tobian AAR, Gehrie EA, Ness PM, & Bloch EM. Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low-resource settings. *Vox Sanguinis* 2018 ; 113 : 3-12.
 49. Mishra KK, Trivedi A, Sosa S, Patel K, Ghosh K. NAT positivity in seronegative voluntary blood donors from western India. *Transfusion and Apheresis Science*. 2017;56:175-178.
DOI: 10.1016/j.transci.2016.11.003
 50. Yooda AP, Soubeiga ST, Yacouba Nebie K, Diarra B, Sawadogo S, Ouattara AK, et al. Impact of multiplex PCR in reducing the risk of residual transfusion-transmitted human immunodeficiency and hepatitis B and C viruses in Burkina Faso. *Mediterr J Hematol Infect Dis*. 2018 ;10:e2018041.

- DOI: 10.4084/mjhid.2018.041
51. Pawar A, Jagani R, Dimri U, Kumar S. Experience of individual donor nucleic acid testing on screening of blood donors for human immunodeficiency virus, Hepatitis C Virus, and Hepatitis B Virus at an Apex blood bank of Northern India. Medical Journal of Dr DY Patil Vidyapeeth [Internet]. Medknow. 2021;0(0):0.
- DOI:10.4103/mjdrdypu.mjdrdypu_344_20.
52. Lv X, Rodgers MA, Yin P, Ke L, Fu P, Wu B, et al. Molecular surveillance of HIV, HBV, and HCV amongst blood donors in five Chinese regions. Cold Spring Harbor Laboratory; 2020.
DOI:10.1101/2020.01.22.916320

© 2021 Mangala et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle4.com/review-history/70484>